ReviewFrontiers in neuroscience2015
Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management.
Review in Frontiers in neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Peripheral Blood-Based Gene Expression Studies in Schizophrenia: A Systematic Review.Frontiers in genetics · 2021Pooled it
- Mediterranean Diet and its Benefits on Health and Mental Health: A Literature Review.Clinical practice and epidemiology in mental health : CP & EMH · 2020Pooled it
- Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review.Molecular psychiatry · 2016Pooled it
- Antipsychotics for fibromyalgia in adults.The Cochrane database of systematic reviews · 2016Pooled it
- Trial
- Effects of a Mediterranean Diet Intervention on Maternal Stress, Well-Being, and Sleep Quality throughout Gestation-The IMPACT-BCN Trial.Nutrients · 2023Trial
- Associations between second-generation antipsychotics and metabolic outcomes in patients with schizophrenia and metabolic abnormalities.Schizophrenia (Heidelberg, Germany) · 2026Article
- Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study.Healthcare (Basel, Switzerland) · 2025Article
- Trends in schizophrenia-related mortality from 1999 to 2020: year, gender, and regional variations.Annals of medicine and surgery (2012) · 2025Review
- North Carolina Healthy Active Living: Describing a Wellness Coaching Program for First-Episode Psychosis Clinics.American journal of lifestyle medicine · 2025Article
- Observational
- Changed expression of placental transporters and disrupted epigenetic patterns in a rat model of schizophrenia.Frontiers in pharmacology · 2025Article
- Association of antipsychotic drugs on type 2 diabetes mellitus risk in patients with schizophrenia: a population-based cohort and in vitro glucose homeostasis-related gene expression study.BMC psychiatry · 2024Article
- The impact of providing care for physical health in severe mental illness on informal carers: a qualitative study.BMC psychiatry · 2024Article
- Weight change following diagnosis with psychosis: a retrospective cohort study in Greater Manchester, UK.Annals of general psychiatry · 2024Article
- Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance.World journal of psychiatry · 2023Article
- First episode psychosis and weight gain a longitudinal perspective in Cheshire UK: a comparison between individuals with nonaffective versus affective psychosis.Cardiovascular endocrinology & metabolism · 2023Article
- The impact of body mass index on the pregnancy outcomes and risk of perinatal depression: Findings from a multicenter Italian study.European psychiatry : the journal of the Association of European Psychiatrists · 2023Article
- Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia.Therapeutic advances in psychopharmacology · 2023Review
- The benefits of the Mediterranean diet in first episode psychosis patients taking antipsychotics.Toxicology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients affected by psychotic disorders are more likely to develop high rates of co-morbidities, such as obesity, type 2 diabetes, dyslipidemias, hypertension, metabolic syndrome, myocardial infarction, stroke etc., in the long-term. These morbidities have a significant impact on the life-expectancy of these patients. Patients with chronic psychoses show a 2-3-fold increased risk of death mostly from cardiovascular and metabolic diseases. Although there may be an independent link, between schizophrenia and metabolic conditions the cardio-metabolic risk is mostly related to an unhealthy lifestyle and the usage of antipsychotic agents (especially Second Generation Antipsychotics or atypical) even when these remain effective treatments in the management of major psychoses. Recently, many international organizations have developed screening and monitoring guidelines for the control of modifiable risk factors in order to reduce the rate of co-morbidity and mortality among patients affected by schizophrenia. This paper is a review of current knowledge about the metabolic issues of patients affected by schizophrenia and describes clinical characteristics and medical management strategies for such conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.